Savings shell game? Lawsuit 'not going to result in big change' in pricing, one PBM rep says

Galentine, Elizabeth
December 2009
Employee Benefit News;Dec2009, Vol. 23 Issue 15, p128
The article focuses on a lawsuit filed against drug wholesaler McKesson Corp. and publishers First Databank and Medi-Span that is said to have led to the reduction of average wholesale price (AWP) in the U.S. They were accused of artificially raising the prices of several prescription drugs by 5%. Jennifer Kingsley Wilson of ARMSRx stressed the need for employers to audit their pharmacy benefit managers (PBMs) to make sure that such a change is made in a price-neutral way. John Jones of Prescription Solutions says the change will not be sustainable.


Related Articles

  • Employers leery of drug-pricing settlement. NOEL, ROB // Employee Benefit News;Dec2009, Vol. 23 Issue 15, p1 

    The article reports on the concerns among employers regarding changes in drug prices made by pharmacy benefit managers (PBMs) after the U.S. District Court of Massachusetts ruled against McKesson Corp., First Databank and Medi-Span on September 26, 2009 in a class-action suit. The court ordered...

  • Accusations against drug wholesaler expand. McLeod, Douglas // Business Insurance;6/9/2008, Vol. 42 Issue 23, p3 

    The article reports that the state of Connecticut and the San Francisco Health Plan have filed separate civil racketeering lawsuits against pharmaceutical wholesaling company McKesson Corp. in the U.S. District Court in Boston, Massachusetts. The suits charge the company of fraudulently adding a...

  • Judge freezes AWP pricing settlement.  // Drug Store News;2/11/2008, Vol. 30 Issue 2, p3 

    The article discusses the rejection on the proposed settlements of class-action lawsuits brought by employers, unions and other health plan payers against drug data publisher First DataBank Inc. and Medi-Span Inc. in Alexandria, Virginia. U.S. District Court Judge Patti Saris of Massachusetts...

  • McKesson legal saga nears end. Robeznieks, Andis // Modern Healthcare;2/27/2006, Vol. 36 Issue 9, p9 

    The article reports the ending of a 1999 corporate accounting scandal faced by McKesson as of February 27, 2006. The case was closed when U.S. District Judge Ronald Whyte approved a $960 million settlement with company shareholders. The lawsuit stemmed from allegations that the defendants harmed...

  • The AWP litigation rollercoaster rumbles on. Milenkovich, Ned // Drug Topics;Sep2009, Vol. 153 Issue 9, p24 

    The article reports that the class-action lawsuit filed by a third-party payor against First DataBank Inc. and McKesson Corp. regarding the inflated average wholesale price (AWP) of hundreds of drugs will result to a rollback of AWP values in the U.S. It notes that parties that offer...

  • Drug pricing system nixed by pact. Wojcik, Joanne // Business Insurance;10/16/2006, Vol. 40 Issue 42, p1 

    The article reports on the proposed settlement of a class action lawsuit filed against First DataBank Inc. The lawsuit alleged that the U.S. company conspired with McKesson Corp. to increase the average wholesale prices for pharmaceuticals between 2002 and 2005. The settlement of the lawsuit...

  • AWP is back from the dead.  // Drug Topics;2/11/2008, Vol. 152 Issue 3, p8 

    The article reports that Judge Patti Saris has rejected key portions of the First DataBank and Medi-Span settlement that would have ended the reporting of average wholesale price (AWP) data following lawsuits filed by pharmacy organizations in the U.S. The lawsuits alleged that First DataBank,...

  • McKesson may pay $350M to settle suit on drug pricing.  // Medical Device Daily;11/24/2008, Vol. 12 Issue 229, p5 

    The article reports on the $350 million settlement proposed by a Seattle, Washington-based law firm representing consumers and third party payers to healthcare services company McKesson to settle allegations that the company fraudulently inflated the price of more than 400 prescription drugs by...

  • Federal Court Judge Certifies Hagens Berman Municipal Class Action against McKesson over Drug Price Manipulation.  // Biomedical Market Newsletter;3/31/2011, p561 

    The article discusses a court case wherein Hagens Berman Sobol Shapiro LLP has charged McKesson Corp. for alleged inflation on drug price scheme of more than 400 brand-name prescription drugs in the U.S. The prescription drugs involved in the McKesson scheme include Prozac, Lipitor, Zocor and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics